Mouse Anti-BRD9 Antibody (1H8) (CBMAB-0174-YC)

Wang, L., Oh, T. G., Magida, J., Estepa, G., Obayomi, S. B., Chong, L. W., ... & Evans, R. M. (2021). Bromodomain containing 9 (BRD9) regulates macrophage inflammatory responses by potentiating glucocorticoid receptor activity. Proceedings of the National Academy of Sciences, 118(35).

Fang, D., Wang, M. R., Guan, J. L., Han, Y. Y., Sheng, J. Q., Tian, D. A., & Li, P. Y. (2021). Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway. Experimental Cell Research, 406(2), 112727.

Zhou, Q., Huang, J., Zhang, C., Zhao, F., Kim, W., Tu, X., ... & Yuan, J. (2020). The bromodomain containing protein BRD-9 orchestrates RAD51–RAD54 complex formation and regulates homologous recombination-mediated repair. Nature communications, 11(1), 1-13.

Dou, C., Sun, L., Wang, L., Cheng, J., Wu, W., Zhang, C., ... & Liu, J. (2020). Bromodomain-containing protein 9 promotes the growth and metastasis of human hepatocellular carcinoma by activating the TUFT1/AKT pathway. Cell death & disease, 11(9), 1-15.

Clegg, M. A., Bamborough, P., Chung, C. W., Craggs, P. D., Gordon, L., Grandi, P., ... & Humphreys, P. G. (2020). Application of atypical acetyl-lysine methyl mimetics in the development of selective inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains. Journal of medicinal chemistry, 63(11), 5816-5840.

Wang, Y., Wang, L. F., Zhang, L. L., Sun, H. B., & Zhao, J. (2020). Molecular mechanism of inhibitor bindings to bromodomain-containing protein 9 explored based on molecular dynamics simulations and calculations of binding free energies. SAR and QSAR in Environmental Research, 31(2), 149-170.

Karim, R. M., Chan, A., Zhu, J. Y., & Schönbrunn, E. (2020). Structural basis of inhibitor selectivity in the BRD7/9 subfamily of bromodomains. Journal of medicinal chemistry, 63(6), 3227-3237.

Bell, C. M., Raffeiner, P., Hart, J. R., & Vogt, P. K. (2019). PIK3CA cooperates with KRAS to promote MYC activity and tumorigenesis via the bromodomain protein BRD9. Cancers, 11(11), 1634.

Crawford, T. D., Vartanian, S., Côté, A., Bellon, S., Duplessis, M., Flynn, E. M., ... & Stokoe, D. (2017). Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. Bioorganic & medicinal chemistry letters, 27(15), 3534-3541.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols